NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas  1  2  3  4  5  » 
found files: 188
AstraZeneca »17/02/2007 [Company watch]
AstraZeneca Wins 2nd Award for Investment in China

Following $134millions investment in a manufacturing plant at Wuxi in 2001, AZ have announced a further $35millions investment in the site. In May 2006 AZ announced its intention to invest $100millions in R & D in China....   more»


Novartis »11/02/2007 [Company watch]
Novartis to focus on Hepatitus drugs in China

Novartis will launch a product for hepatitus B this year as it is China\\\'s prevalent disease with approx 20 million affected. CEO Vasella says they have been growing by 20% on average over the last 5 years and gained considerable market share....   more»


Novo Nordisk »05/03/2007 [Company watch]
Novo Nordisk and Chinese Academy of Science establish Research Foundation

Novo Nordisk have committed $2million to co-fund research activities of mutual interest - diabetes and biopharmaceuticals....   more»


AstraZeneca »23/03/2007 [Company watch]
AStraZeneca name site for lab expansion plan

AStrazeneca confirm site for their $100Million R & D expansion in China as the Zhangjiang Hi-Tech park in Shanghai with completion due in mid 2007. Recruitrment of scientists is already underway. The Innovation Center China will open in mid-2007 before the establishment of a permanent site that officials are still looking for....   more»


Wyeth »01/04/2007 [Company watch]
Wyeth considering relocation from China to India

Exasperated by the slow pace of regulatory procedures in China for the approval of new drugs, American pharmaceutical and healthcare giant Wyeth is believed to be exploring the option of relocating its Asian drugs research operations from China to India. Sherry Ku, Wyeth’s senior director in China, has been quoted in the local media as saying on the sidelines of a pharmaceutical conference in Hainan province that, while there was, as of now, no timetable for shifting to India, such a move was possible, even inevitable, if the regulatory environment in mainland China did not improve....   more»


Bayer »28/03/2007 [Other]
Bayer CropScience aims to grow in China:

Bayer CropScience aims to grow in China: Sales in the People's Republic forecast to top EUR 100 million in the medium term Plans for two joint ventures for hybrid rice business and expansion of crop protection production...   more»


AstraZeneca »24/04/2007 [Company watch]
AStra Zeneca are advertising for :TRANSLATIONAL SCIENTIST for pre-clinical development in cancer research

AStra Zeneca are seeking an experienced scientist to lead pre clinical cancer trials team in the Shanghai Innovation Centre - full job advert below, to be fully operational by 2009...   more»


Novo Nordisk »03/05/2007 [Company watch]
Novo Nordisk will continue to exploit the emerging importance of China in pharma research by establishing a new diabetes research foundation there.

UPDATE: The Danish pharma company is setting up a joint science research foundation with the Chinese Academy of Science (CAS). The collaboration will concentrate on diabetes and biopharmaceuticals research, including related fields and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology and drug delivery....   more»


Johnson & Johnson »15/04/2007 [Company watch]
Johnson & Johnson Buys China’s Dabao

China ’s largest cosmetic manufacturer, Dabao, has reportedly been bought by Johnson and Johnson (J&J) for 2.3 billion Yuan (approximately US$299 million)....   more»


GlaxoSmithKline »03/05/2007 [Company watch]
China recognises GSK for busting fake drugs racket

Undercover agents employed by GlaxoSmithKline (GSK) posed as traders in fake medicines to help to close down a global pharmaceutical counterfeiting racket based in China...   more»


Novartis »23/04/2007 [Company watch]
Novartis with dynamic growth in the 2007 first quarter

Strong 2007 first quarter performance as Group net sales advance 18% (+15% in local currencies) to USD 9.8 billion on excellent performances from all divisions Group continuing operations operating income up 18%, net income up 17%...   more»


Eli Lilly & Co »04/05/2007 [Company watch]
Lilly Announces Senior Leadership Changes

Alex M. Azar II to join Lilly as senior vice president of corporate affairs and communications; Anne Nobles to assume role of chief compliance officer...   more»


Eli Lilly & Co »16/04/2007 [Company watch]
Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales and EPS Guidance

Eli Lilly and Company (NYSE: LLY) today announced strong financial results for the first quarter of 2007 and raised its full-year sales and adjusted earnings per share guidance. First-Quarter Highlights * Sales increased 14 percent, to $4.226 billion....   more»


Wyeth »27/04/2007 [Company watch]
Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin to Leave the Company

Madison, N.J., April 27, 2007 – Wyeth (NYSE: WYE) today announced that Chief Financial Officer (CFO) and Vice Chairman Kenneth J. Martin has announced plans to leave the Company at the end of June to pursue personal interests. Mr. Martin joined the Company in 1984 and has served as Chief Financial Officer since 2000. Wyeth plans to name a new CFO in advance of Mr. Martin’s departure. "Ken Martin has played key roles at Wyeth for many years and has been an important contributor to our success," says Robert Essner, Chairman and Chief Executive Officer, Wyeth...   more»


GlaxoSmithKline »23/05/2007 [Company watch]
Glaxo to unveil major China drug research centre

LONDON, May 23 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile , Research) is set to unveil plans for major research and development centre in China, joining a growing number of pharmaceutical companies tapping into the country's skillbase in life sciences. Research head Moncef Slaoui told the annual meeting of Europe's biggest drugmaker on Wednesday that an announcement on the investment in a fully integrated research and development facility was imminent....   more»


Amgen »22/05/2007 [Company watch]
Amgen (NASDAQ:AMGN) today announced that David Lacey, M.D., has been named senior vice president, head of Research, effective immediately.

Amgen (NASDAQ:AMGN) today announced that David Lacey, M.D., has been named senior vice president, head of Research, effective immediately. Over the past year, Lacey acted as the interim head of Research -- in addition to his role as Amgen South San Francisco site leader -- and demonstrated his ability to effectively manage Amgen's global Research organization, encompassing the company's Oncology/Hematology, Inflammation, Metabolic Disorders and Neuroscience therapeutic areas...   more»


GlaxoSmithKline »24/05/2007 [Company watch]
GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai

Jingwu Zang to lead work on neurogenerative diseases GlaxoSmithKline (GSK) today announces the appointment of Jingwu Zang to head a new GSK research and development centre in Shanghai, China. His appointment, as Senior Vice President, will be effective in June....   more»


Pfizer »24/05/2007 [Industry news]
Pfizer Says Research and Development Head John LaMattina Will Retire This Year

Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company’s research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and outside the company for his successor, and Dr. LaMattina has agreed to remain during this period to ensure a smooth transition....   more»


Merck & Co »20/05/2007 [Industry news]
Merck Announces Resignation of Peter Loescher, President, Global Human Health

WHITEHOUSE STATION, N.J., May 20, 2007 - Merck & Co., Inc. today announced the resignation of Peter Loescher, president, Global Human Health. Effective July 1, 2007, Mr. Loescher, 49, will take on the position of president and chief executive officer at Siemens AG. "We thank Peter for his contributions to Merck and wish him and his family well in this new endeavor," said Richard T. Clark, chairman, president and chief executive officer. "Merck remains fully committed to the strategic initiatives and operating goals established for the Global Human Health (GHH) organization. We continue to be pleased with the strong business performance across all the GHH franchises and regions, and we are confident that it will continue." Mr. Loescher will remain for a period of time to help with the leadership transition. Merck expects to name a new leader for the GHH organization so...   more»


GlaxoSmithKline »29/05/2007 [Company watch]
GlaxoSmithKline set up a drug research centre in China.

GlaxoSmithKline (GSK) is the latest pharma heavyweight to set up a drug research centre in China....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.